Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in Non-Target Tumors Favorable Safety Profile ...
A new T-cell therapy showed benefits in patients with relapsed/refractory multiple myeloma. Patients with relapsed/refractory multiple myeloma benefited from treatment with MCARH109, a CAR-T cell ...
An estimated 2.8 million people worldwide have multiple sclerosis (MS). This autoimmune condition is the result of the immune system damaging parts of the nerves in the brain and spinal cord, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results